In this episode of the Investor Podcast, we sit down with William Solomon, Chief Investment Officer at White Manna Capital, to explore the intersection of artificial intelligence, biotechnology, metabolic disease, and women’s health. With over two decades of leadership spanning clinical research, pharmaceutical regulatory affairs, and entrepreneurship—including founding the Accreditation Council for Medical Affairs (ACMA)—William brings a unique, operator-led perspective to public equity investing and hedge fund strategy.
The conversation dives deep into:
The Evolution of GLP-1s & Metabolic Health: Moving past short-term weight loss toward targeting organ damage, preserving lean muscle mass, and evaluating the next generation of therapeutics from leaders like Eli Lilly, Structure Therapeutics, and Viking Therapeutics.
Emerging Health Infrastructure & AI: How digital health platforms, continuous glucose monitors (CGMs), wearables, and anonymized big data warehouses are enabling precision medicine while maintaining essential human-in-the-loop oversight.
Building an Institutional Hedge Fund: Tactical advice for emerging managers on maintaining lean operational structures, managing single-stock concentration risk (capping movers around 10%), and clearly articulating a differentiated investment edge to prospective LPs.
Innovations in Women’s Health & Longevity: Addressing metabolic shifts, perimenopause, cardiovascular risk, and bone density preservation as life expectancies continue to extend.
William concludes the discussion with a vital lesson on leadership and team building: "When people show you who they are when you first meet them, believe them."
Podden och tillhörande omslagsbild på den här sidan tillhör
Dr. Joel Palathinkal. Innehållet i podden är skapat av Dr. Joel Palathinkal och inte av,
eller tillsammans med, Poddtoppen.
